

What reinfections mean for COVID-19

Lancet Infectious Diseases, The
21, 3-5

DOI: 10.1016/s1473-3099(20)30783-0

Citation Report

#	ARTICLE	IF	CITATIONS
1	Coronavirus vaccine development: from SARS and MERS to COVID-19. Journal of Biomedical Science, 2020, 27, 104.	7.0	287
2	Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clinical Microbiology and Infection, 2021, 27, 315-318.	6.0	141
3	A case of SARS-CoV-2 reinfection in Ecuador. Lancet Infectious Diseases, The, 2021, 21, e142.	9.1	72
4	Ct values and infectivity of SARS-CoV-2 on surfaces. Lancet Infectious Diseases, The, 2021, 21, e141.	9.1	41
5	Blood Biomarkers for Detection of Brain Injury in COVID-19 Patients. Journal of Neurotrauma, 2021, 38, 1-43.	3.4	68
6	Serological Evidence for Reinfection with SARS-CoV-2; An Observational Cohort Study. SSRN Electronic Journal, 0, , .	0.4	1
7	A fractional complex network model for novel corona virus in China. Advances in Difference Equations, 2021, 2021, 5.	3.5	4
8	Preparing for the Coronavirus Disease (COVID-19) Vaccination: Evidence, Plans, and Implications. Journal of Korean Medical Science, 2021, 36, e59.	2.5	51
9	Immune determinants of COVID-19 disease presentation and severity. Nature Medicine, 2021, 27, 28-33.	30.7	490
11	Evidence for immunity to SARS-CoV-2 from epidemiological data series. F1000Research, 0, 10, 50.	1.6	0
12	Impaired anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with diabetes mellitus: A preliminary report. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 193-196.	3.6	34
14	Towards Bayesian Evaluation of Seroprevalence Studies. Medical Sciences Forum, 2021, 4, .	0.5	0
15	Clinical characteristics of re-hospitalized COVID-19 patients with recurrent positive SARS-CoV-2 RNA: a retrospective study. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1245-1252.	2.9	8
16	Do Antibody Positive Healthcare Workers Have Lower SARS-CoV-2 Infection Rates than Antibody Negative Healthcare Workers? Large Multi-Centre Prospective Cohort Study (The SIREN Study), England: June to November 2020. SSRN Electronic Journal, 0, , .	0.4	7
17	Herd immunity by infection is not an option. Science, 2021, 371, 230-231.	12.6	47
18	The 2020 race towards SARS-CoV-2 specific vaccines. Theranostics, 2021, 11, 1690-1702.	10.0	71
19	Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS-CoV-2. The Cochrane Library, 0, , .	2.8	4
20	Epidemiological characteristics, reinfection possibilities and vaccine development of SARS CoV2: A global review. Journal of Family Medicine and Primary Care, 2021, 10, 1095.	0.9	3

#	ARTICLE	IF	CITATIONS
21	Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19. Heliyon, 2021, 7, e05951.	3.2	15
22	SARS-CoV-2: vaccines in the pandemic era. Military Medical Research, 2021, 8, 1.	3.4	104
23	Looking beyond COVID-19 vaccine phase 3 trials. Nature Medicine, 2021, 27, 205-211.	30.7	473
24	Dynamics of a Dual SARS-CoV-2 Lineage Co-Infection on a Prolonged Viral Shedding COVID-19 Case: Insights into Clinical Severity and Disease Duration. Microorganisms, 2021, 9, 300.	3.6	48
25	Comparison of nasopharyngeal samples for SARS-CoV-2 detection in a paediatric cohort. Journal of Paediatrics and Child Health, 2021, 57, 1078-1081.	0.8	3
26	COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity, 2021, 54, 340-354.e6.	14.3	177
27	SARS-COV-2, can you be over it?. World Allergy Organization Journal, 2021, 14, 100514.	3.5	6
28	Suspected Recurrent SARS-CoV-2 Infections Among Residents of a Skilled Nursing Facility During a Second COVID-19 Outbreak – Kentucky, July–November 2020. Morbidity and Mortality Weekly Report, 2021, 70, 273-277.	15.1	24
29	Persistent viral RNA shedding in COVID-19: Caution, not fear. EBioMedicine, 2021, 64, 103234.	6.1	15
30	Noncompliance With Safety Guidelines as a Free-Riding Strategy: An Evolutionary Game-Theoretic Approach to Cooperation During the COVID-19 Pandemic. Frontiers in Psychology, 2021, 12, 646892.	2.1	48
33	Repeated SARS-CoV-2 Positivity: Analysis of 123 Cases. Viruses, 2021, 13, 512.	3.3	24
34	The Impact of Increasing Disease Prevalence, False Omissions, and Diagnostic Uncertainty on Coronavirus Disease 2019 (COVID-19) Test Performance. Archives of Pathology and Laboratory Medicine, 2021, 145, 797-813.	2.5	14
35	Clinical characteristics of SARS-CoV-2 by re-infection vs. reactivation: a case series from Iran. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1713-1719.	2.9	24
36	Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. Nephrology Dialysis Transplantation, 2021, 36, 1160-1168.	0.7	38
37	Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG lateral flow assay. PLoS ONE, 2021, 16, e0247797.	2.5	20
38	Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nature Immunology, 2021, 22, 620-626.	14.5	320
41	A Case Series Describing the Recurrence of COVID-19 in Patients Who Recovered from Initial Illness in Bangladesh. Tropical Medicine and Infectious Disease, 2021, 6, 41.	2.3	9
42	The first 12 months of COVID-19: a timeline of immunological insights. Nature Reviews Immunology, 2021, 21, 245-256.	22.7	325

#	ARTICLE	IF	CITATIONS
44	Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review. PLoS ONE, 2021, 16, e0248946.	2.5	71
46	SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet, The, 2021, 397, 1459-1469.	13.7	557
47	Incorporating Social Determinants of Health into Modelling of COVID-19 and other Infectious Diseases: A Baseline Socio-economic Compartmental Model. Social Science and Medicine, 2021, 274, 113794.	3.8	31
49	COVID-19 Reinfection in a Patient Receiving Immunosuppressive Treatment for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis and Rheumatology, 2021, 73, 1091-1092.	5.6	9
50	HOW COVID-19 PATIENT NARRATIVES CONCERNING REINFECTION MIRROR THEIR MENTAL HEALTH: A CASE SERIES. Psychiatria Danubina, 2021, 33, 114-119.	0.4	5
51	The COVID-19 Vaccine in Clinical Trials: Where Are We Now?. Infectious Diseases & Immunity, 2021, 1, 43-51.	0.6	4
52	Pandemic analysis of infection and death correlated with genomic open reading frame 10 mutation in severe acute respiratory syndrome coronavirus 2 victims. Journal of the Chinese Medical Association, 2021, 84, 478-484.	1.4	12
53	Reinfection of SARS-CoV-2 – analysis of 23 cases from the literature. Infectious Diseases, 2021, 53, 1-7.	2.8	12
54	Structured serological testing is an essential component to investigating SARS-CoV-2 reinfection. Lancet Infectious Diseases, The, 2021, 21, 598-599.	9.1	1
55	Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study. Clinical Infectious Diseases, 2022, 74, 622-629.	5.8	61
56	SARS-CoV-2 reinfection: Two cases from Ethiopia. , 0, 2, 114-116.		0
58	Analysis of the potential impact of durability, timing, and transmission blocking of COVID-19 vaccine on morbidity and mortality. Eclinicalmedicine, 2021, 35, 100863.	7.1	35
59	Evidence for immunity to SARS-CoV-2 from epidemiological data series. F1000Research, 0, 10, 50.	1.6	0
60	SARS-CoV-2 Reinfection among Healthcare Workers in Mexico: Case Report and Literature Review. Medicina (Lithuania), 2021, 57, 442.	2.0	10
61	Prolonged viral shedding and antibody persistence in patients with COVID-19. Microbes and Infection, 2021, 23, 104810.	1.9	23
62	Dynamics of SARS-CoV-2 with waning immunity in the UK population. Philosophical Transactions of the Royal Society B: Biological Sciences, 2021, 376, 20200274.	4.0	31
63	Modeling COVID-19 with Uncertainty in Granada, Spain. Intra-Hospitalary Circuit and Expectations over the Next Months. Mathematics, 2021, 9, 1132.	2.2	2
64	Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection. JAMA Internal Medicine, 2021, 181, 672.	5.1	236

#	ARTICLE	IF	CITATIONS
65	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. The Cochrane Library, 2021, 2021, CD013600.	2.8	109
66	Re-Infection by SARS-Cov-2 with in 5 Months: A Case Report. Biomedical and Pharmacology Journal, 2021, 14, 577-581.	0.5	0
67	Coronavirus new variants: the mutations cause and the effect on the treatment and vaccination. Baghdad Journal of Biochemistry and Applied Biological Sciences, 2021, 2, 71-79.	0.9	9
68	Risk of Symptomatic Infection During a Second Coronavirus Disease 2019 Wave in Severe Acute Respiratory Syndrome Coronavirus 2-Seropositive Individuals. Clinical Infectious Diseases, 2022, 74, 893-896.	5.8	5
69	Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative. Advanced Science, 2021, 8, e2100985.	11.2	16
70	Microglial Implications in SARS-CoV-2 Infection and COVID-19: Lessons From Viral RNA Neurotropism and Possible Relevance to Parkinson's Disease. Frontiers in Cellular Neuroscience, 2021, 15, 670298.	3.7	40
71	Persistent SARS-CoV-2 positivity. Infectious Diseases in Clinical Practice, 2021, 29, e328-e329.	0.3	7
72	From Isolation to Containment: Perceived Fear of Infectivity and Protective Behavioral Changes during the COVID-19 Vaccination Campaign. International Journal of Environmental Research and Public Health, 2021, 18, 6503.	2.6	14
73	Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. Kidney International, 2021, 99, 1470-1477.	5.2	58
74	Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study. The Lancet Healthy Longevity, 2021, 2, e362-e370.	4.6	60
75	Mathematical modelling of the second wave of COVID-19 infections using deterministic and stochastic SIRD models. Nonlinear Dynamics, 2021, 106, 1359-1373.	5.2	8
76	Reinfection or relapse of COVID-19 in health care workers; case series of 2 patients from Pakistan. New Microbes and New Infections, 2021, 42, 100896.	1.6	2
77	Recurrent COVID-19 infection in a health care worker: a case report. Journal of Medical Case Reports, 2021, 15, 363.	0.8	4
78	COVID-19: a confirmed case of reinfection in a nurse. BMJ Case Reports, 2021, 14, e244507.	0.5	6
79	Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. PLoS ONE, 2021, 16, e0253977.	2.5	35
80	A clinical case of the novel coronavirus (COVID-19) reinfection in a health care worker. Rossiiskii Meditsinskii Zhurnal: Organ Ministerstva Zdravookhraneniia RSFSR, 2021, 27, 195-200.	0.1	0
81	Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2. Viral Immunology, 2021, 34, 504-509.	1.3	5
82	Vaccine Innovation for Pandemic Preparedness: Patent Landscape, Global Sustainability, and Circular Bioeconomy in Post-COVID-19 era. Circular Economy and Sustainability, 2021, 1, 1439-1461.	5.5	8

#	ARTICLE	IF	CITATIONS
83	Modeling the COVID-19 pandemic: a primer and overview of mathematical epidemiology. <i>SeMA Journal</i> , 2022, 79, 225-251.	2.0	17
84	Vaccination certificates, immunity passports, and test-based travel licences: Ethical, legal, and public health issues. <i>Travel Medicine and Infectious Disease</i> , 2021, 42, 102079.	3.0	3
85	Recurrent and persistent infection with SARS-CoV-2 â€“ epidemiological data and case reports from Western Sweden, 2020. <i>Infectious Diseases</i> , 2021, 53, 900-907.	2.8	13
86	Distinguishing repeated polymerase chain reaction positivity from reâ€“infections in COVIDâ€“19. <i>Influenza and Other Respiratory Viruses</i> , 2021, 15, 742-749.	3.4	1
87	Severe acute respiratory syndrome coronavirus 2 reinfection in a coronavirus disease 2019 recovered young adult: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 382.	0.8	3
90	COVID-19 false dichotomies and a comprehensive review of the evidence regarding public health, COVID-19 symptomatology, SARS-CoV-2 transmission, mask wearing, and reinfection. <i>BMC Infectious Diseases</i> , 2021, 21, 710.	2.9	118
93	Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. <i>PLoS ONE</i> , 2021, 16, e0255335.	2.5	48
94	COVID-19 Reinfection in a Young Medical Doctor: A Case Report. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 712-715.	0.4	0
95	COVID-19 Testing and the Impact of the Pandemic on the Miami Adult Studies on HIV Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 1016-1023.	2.1	21
96	COVID-19 Research: Lessons from Non-Human Primate Models. <i>Vaccines</i> , 2021, 9, 886.	4.4	15
99	Containing epidemics in a local cluster via antidote distribution and partial quarantine. <i>Physical Review E</i> , 2021, 104, 034307.	2.1	0
100	Vaccination passports: Challenges for a future of air transportation. <i>Transport Policy</i> , 2021, 110, 394-401.	6.6	30
101	A review of mathematical model-based scenario analysis and interventions for COVID-19. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 209, 106301.	4.7	37
102	Complexities in Case Definition of SARS-CoV-2 Reinfection: Clinical Evidence and Implications in COVID-19 Surveillance and Diagnosis. <i>Pathogens</i> , 2021, 10, 1262.	2.8	0
103	Airborne infection risks of SARS-CoV-2 in U.S. schools and impacts of different intervention strategies. <i>Sustainable Cities and Society</i> , 2021, 74, 103188.	10.4	23
105	COVID-19 vaccination drive in India â€“ Beginning of the end. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 2726.	0.9	0
106	Why decoding the immune response to COVID matters for vaccines. <i>Nature</i> , 2020, 586, 473-474.	27.8	4
112	A case of COVID-19 reinfection in the UK. <i>Clinical Medicine</i> , 2021, 21, e52-e53.	1.9	52

#	ARTICLE	IF	CITATIONS
113	Virtual screening of functional foods and dissecting their roles in modulating gene functions to support post COVID-19 complications. Journal of Food Biochemistry, 2021, 45, e13961.	2.9	11
114	Hyperimmune immunoglobulin for people with COVID-19. The Cochrane Library, 2021, 2021, .	2.8	0
115	The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome. Interface Focus, 2021, 11, 20210008.	3.0	24
117	Nationwide assessment of energy costs and policies to limit airborne infection risks in U.S. schools. Journal of Building Engineering, 2022, 45, 103533.	3.4	1
120	CORONAVIRUS VACCINE DEVELOPMENT: FROM SARS AND MERS TO COVID-19 (RUSSIAN TRANSLATION). Juvenis Scientia, 2020, 6, 41-80.	0.2	0
121	Reinfection and Breakthrough Infection of SARS-CoV-2: An Emerging Challenge That Is Threatening Our World. Infectious Diseases & Immunity, 2022, 2, 29-33.	0.6	3
127	COVID-19 vaccinations: The unknowns, challenges, and hopes. Journal of Medical Virology, 2022, 94, 1336-1349.	5.0	75
128	Evaluation of the United States COVID-19 vaccine allocation strategy. PLoS ONE, 2021, 16, e0259700.	2.5	22
129	It took it off most of the time 'cause I felt comfortable' - unmasking, trusted others, and lessons learned from a coronavirus disease 2019 reinfection: a case report. Journal of Medical Case Reports, 2021, 15, 557.	0.8	1
130	SARS-CoV-2 re-infection rate in Iranian COVID-19 cases within one-year follow-up. Microbial Pathogenesis, 2021, 161, 105296.	2.9	23
131	Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. Future Microbiology, 2021, 16, 1415-1451.	2.0	12
132	The mystery of COVID-19 reinfections: A global systematic review and meta-analysis. Annals of Medicine and Surgery, 2021, 72, 103130.	1.1	31
133	Evaluating COVID-19 Booster Vaccination Strategies in a Partially Vaccinated Population: A Modeling Study. SSRN Electronic Journal, 0, , .	0.4	0
135	Dynamic data-driven algorithm to predict cumulative COVID-19 infected cases using susceptible-infected-susceptible model. Epidemiologic Methods, 2021, 10, .	0.9	3
136	Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse. , 2021, 25, .		4
137	Regression Models for Understanding COVID-19 Epidemic Dynamics With Incomplete Data. Journal of the American Statistical Association, 2021, 116, 1561-1577.	3.1	16
138	The Different Immune Responses by Age Are due to the Ability of the Fetal Immune System to Secrete Primal Immunoglobulins Responding to Unexperienced Antigens. International Journal of Biological Sciences, 2022, 18, 617-636.	6.4	2
139	The changing dynamics of neutralizing antibody response within 10 months of SARS-CoV-2 infections. Journal of Medical Virology, 2021, , .	5.0	2

#	ARTICLE	IF	CITATIONS
140	The prevalence of adaptive immunity to COVID-19 and reinfection after recovery – a comprehensive systematic review and meta-analysis. <i>Pathogens and Global Health</i> , 2022, 116, 269-281.	2.3	27
142	COVID-19 reinfections among naturally infected and vaccinated individuals. <i>Scientific Reports</i> , 2022, 12, 1438.	3.3	79
143	Sexual dimorphism in COVID-19: potential clinical and public health implications. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 221-230.	11.4	78
146	The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine. <i>Annals of Internal Medicine</i> , 2022, 175, 674-681.	3.9	45
148	Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models. <i>Viruses</i> , 2022, 14, 449.	3.3	5
149	Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2. <i>BMC Immunology</i> , 2022, 23, 7.	2.2	6
150	Multiple COVID-19 Waves and Vaccination Effectiveness in the United States. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2282.	2.6	36
151	Dynamical analysis of the infection status in diverse communities due to COVID-19 using a modified SIR model. <i>Nonlinear Dynamics</i> , 2022, 109, 19-32.	5.2	5
152	COVID-19 reinfection in Liberia: Implication for improving disease surveillance. <i>PLoS ONE</i> , 2022, 17, e0265768.	2.5	7
153	Clinical Features and Time to Recovery of Admitted COVID-19 Cases at Dilla University Referral Hospital Treatment Center, South Ethiopia. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 795-806.	2.7	5
154	Reinfection in COVID-19: Do we exaggerate our worries?. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13767.	3.4	11
155	Evaluating COVID-19 Booster Vaccination Strategies in a Partially Vaccinated Population: A Modeling Study. <i>Vaccines</i> , 2022, 10, 479.	4.4	9
156	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e545-e551.	5.8	130
157	Modeling Early Phases of COVID-19 Pandemic in Northern Italy and Its Implication for Outbreak Diffusion. <i>Frontiers in Public Health</i> , 2021, 9, 724362.	2.7	2
158	Clinical Presentation and Course of SARS-CoV-2 Infection in Health-Care Personnel Working in Dedicated COVID-19 Hospital During 2 Pandemic Waves in India. <i>Disaster Medicine and Public Health Preparedness</i> , 2021, , 1-6.	1.3	0
159	Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis. <i>Chinese Medical Journal</i> , 2022, 135, 145-152.	2.3	35
160	Protective Effect of Melatonin Administration against SARS-CoV-2 Infection: A Systematic Review. <i>Current Issues in Molecular Biology</i> , 2022, 44, 31-45.	2.4	7
162	The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 916-925.	3.4	11

#	ARTICLE	IF	CITATIONS
164	An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7
166	Modelling how face masks and symptoms-based quarantine synergistically and cost-effectively reduce SARS-CoV-2 transmission in Bangladesh. <i>Epidemics</i> , 2022, 40, 100592.	3.0	4
167	Epidemiological and clinical characteristics of SARS-CoV-2 reinfections in a Spanish region. <i>SAGE Open Medicine</i> , 2022, 10, 205031212211085.	1.8	2
168	The potential of developing a protective peptide-based vaccines against SARS-CoV-2. <i>Drug Development Research</i> , 0, , .	2.9	2
169	Post pandemic fatigue: what are effective strategies?. <i>Scientific Reports</i> , 2022, 12, .	3.3	6
170	Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals. <i>BMC Infectious Diseases</i> , 2022, 22, .	2.9	6
171	Reinfection, recontamination and revaccination for SARS-CoV-2. <i>World Journal of Methodology</i> , 2022, 12, 258-263.	3.5	0
173	Investigation Of The Dentists' Fear Of Covid And Psychological Status During Covid-19 Pandemic. <i>Anadolu KliniÄyi Tıp Bilimleri Dergisi</i> , 0, , .	0.4	0
174	Analysis of multi-strain infection of vaccinated and recovered population through epidemic model: Application to COVID-19. <i>PLoS ONE</i> , 2022, 17, e0271446.	2.5	2
175	Fast and noninvasive electronic nose for sniffing out COVID-19 based on exhaled breath-print recognition. <i>Npj Digital Medicine</i> , 2022, 5, .	10.9	30
177	Laboratory Findings in Different Disease Status of COVID-19 Admitted Patients at Dilla University Referral Hospital Treatment Center, South Ethiopia. <i>Infection and Drug Resistance</i> , 0, Volume 15, 4307-4320.	2.7	1
178	COVID-19 diverse outcomes: Aggravated reinfection, type I interferons and antibodies. <i>Medical Hypotheses</i> , 2022, 167, 110943.	1.5	1
179	Association of Results of Four Lateral Flow Antibody Tests with Subsequent SARS-CoV-2 Infection. <i>Microbiology Spectrum</i> , 0, , .	3.0	2
180	SARS-CoV-2 reinfections during the first three major COVID-19 waves in Bulgaria. <i>PLoS ONE</i> , 2022, 17, e0274509.	2.5	8
181	Activity-driven network modeling and control of the spread of two concurrent epidemic strains. <i>Applied Network Science</i> , 2022, 7, .	1.5	2
182	A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?. <i>Medicine (United States)</i> , 2022, 101, e30609.	1.0	4
184	SARS-CoV-2 infections in certain groups: A review from COVID-19 study cases. <i>AIP Conference Proceedings</i> , 2023, , .	0.4	0
185	Hyperimmune immunoglobulin for people with COVID-19. <i>The Cochrane Library</i> , 2023, 2023, .	2.8	5

#	ARTICLE	IF	CITATIONS
186	Convalescent plasma for people with COVID-19: a living systematic review. The Cochrane Library, 2023, .	2.8	10
187	Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents. Journal of Pediatrics, 2023, 257, 113371.	1.8	4
188	Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation. Lancet Microbe, The, 2023, 4, e495-e505.	7.3	3
189	The Impact of Sputnik SARS-CoV-2 Vaccines on Antibody Response in the Egyptian Population. Open Access Macedonian Journal of Medical Sciences, 2023, 11, 122-126.	0.2	0
190	Wastewater-based modeling, reconstruction, and prediction for COVID-19 outbreaks in Hungary caused by highly immune evasive variants. Water Research, 2023, 241, 120098.	11.3	3
191	Public opinion on COVID-19 vaccine prioritization in Bangladesh: Who gets the vaccine and whom do you leave out?. Vaccine, 2023, 41, 5018-5028.	3.8	0
192	Convalescent plasma for people with COVID-19: a living systematic review. The Cochrane Library, 2024, .	2.8	3
193	Jump-Drop Adjusted Prediction of Cumulative Infected Cases Using the Modified SIS Model. Annals of Data Science, 0, , .	3.2	0
194	Fear and Stigma of COVID-19 Reinfection Scale (FSOCOVID-19RS): New Scale Development and Validation. Healthcare (Switzerland), 2023, 11, 1461.	2.0	0
195	Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study. Wellcome Open Research, 0, 8, 350.	1.8	0
196	COVID-19-Omics Report: From Individual Omics Approaches to Precision Medicine. Reports, 2023, 6, 45.	0.5	0
197	Correlations of demographic factors and hygiene factors with face mask wearing during the COVID-19 pandemic and suggestion for future research: A cross-sectional study of adults in Malaysia. Journal of Public Health Research, 2023, 12, .	1.2	0
198	Low Risk of SARS-CoV-2 Reinfection for Fully or Boosted mRNA Vaccinated Subjects in Sicily: A Population-Based Study Using Real-World Data. Vaccines, 2023, 11, 1757.	4.4	0
200	COVID-19 therapy directed against pathogenic mechanisms of severe acute respiratory syndrome coronavirus 2. , 2024, , 2697-2726.		0
201	Trade-offs and political economy during pandemics. , 2024, , 157-199.		0